BioSpace News Archive

Accuray Incorporated (NASDAQ: ARAY) announced today that the National Institute for Health and Care Excellence (NICE)* has endorsed the use of radiosurgery for trigeminal neuralgia (TN), strengthening the evidence for the company to market its CyberKnife® Treatment Delivery System for this indication in the United Kingdom.

Foldax®, Inc. announced the presentation of results from the first animal study of its transcatheter valve from the TRIA™ biopolymer heart valve portfolio this past weekend at the Cardiovascular Research Technologies annual conference.

Cabaletta Bio, Inc. announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in the Neuromuscular corporate panel discussion at the Cowen Virtual 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET.

Noema Pharma today announces the appointment of Michael Gutch, Ph.D., as Chief Financial Officer.

Zymergen Inc., announced the company will be participating in the upcoming 42nd Annual Cowen Virtual Healthcare Conference.

Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced that the first patient has been dosed in its Phase II proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease.

Amedisys, Inc. announced that Chris Gerard, President and Chief Operating Officer and Scott Ginn, Executive Vice President and Chief Financial Officer, will present at the Raymond James & Associates’ 43rd Annual Institutional Investors Conference on Tuesday, March 8, at 11:35 a.m. EST.

Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that Jeffrey (Jeff) Jones, M.D., MPH, MBA will join the company as Chief Medical Officer and Anne-Marie (Annie) Martin, Ph.D., has been appointed to the Company’s Board of Directors.

Conformis, Inc., the pioneer and leader of fully personalized orthopedic medical devices, announced results of a published retrospective study of patients showing the superiority of Conformis’ implants in several key measures of clinical success and patient satisfaction.

Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, announced the appointment of Ronald Martell as the company’s Chief Executive Officer effective March 15, 2022.